Notice of Proposed Sale · 144
First Tracks Biotherapeutics, Inc.
TRAXNASDAQEQUITYCurrent
Notice of Proposed Sale
Structured filing — 144
primary_doc.xml
Notice of proposed sale. The proposed amounts below do not establish that a sale occurred.
Proposed-sale notice
- Issuer
- FIRST TRACKS BIOTHERAPEUTICS, INC.
- Issuer CIK
- 0002091349
- SEC file number
- 001-43177
- Phone
- (858) 362-6295
- Person for whose account securities are to be sold
- JOE ANTHONY WARE
- Relationships to issuer
- Director
- Street
- 10770 Wateridge Circle, Suite 210
- City
- San Diego
- State / country code
- CA
- Postal code
- 92121
Securities proposed for sale
| Security | Proposed units | Aggregate market value | Units outstanding | Approximate sale date | Exchange | Broker / market maker |
|---|---|---|---|---|---|---|
| Common | 39,265 | 1,758,145.35 | 35,730,843 | 09/02/2026 | NASDAQ | Morgan Stanley Smith Barney LLC Executive Financial Services |
Broker / market maker — proposed row 1, entry 1
- Name
- Morgan Stanley Smith Barney LLC Executive Financial Services
- Street
- 1 New York Plaza
- Street (continued)
- 8th Floor
- City
- New York
- State / country code
- NY
- Postal code
- 10004
Acquisition of securities to be sold
| Security | Acquired | Nature of acquisition | Acquired from | Amount acquired | Gift transaction | Payment date | Nature of payment |
|---|---|---|---|---|---|---|---|
| Common | 09/02/2026 | Stock Option Exercise | Issuer | 39,265 | N | 09/02/2026 | Cash |
Prior-sale reporting
- Nothing to report for the preceding three months
- Y
Notice signature
- Notice date
- 09/02/2026
- Signed
- /s/ Joe Anthony Ware
Company context
We are a clinical stage biotechnology company advancing antibody therapies that modulate immune pathways implicated in autoimmune and inflammatory diseases. Our pipeline includes ANB033, a CD122 antagonist in development for celiac disease and eosinophilic esophagitis; rosnilimab, a pathogenic T cell depleter in development for rheumatoid arthritis; and ANB101, a blood dendritic cell antigen 2 (“BDCA2”) modulator.